Document is current
Any future updates will be listed below
-
Authors
Deutsch, Julie Stein
Lai, Jonathan
Schenk, Kara M
Soni, Abha
Will, Elizabeth M
Engle, Logan L
Xu, Haiying
Ogurtsova, Alexandra
Madan, Vrinda
Chong, Jennifer K
Wang, Daphne
Green, Benjamin F
Nguyen, Peter
Schollenberger, Megan D
Lipson, Evan J https://orcid.org/0000-0003-2976-0911
Taube, Janis M
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct03132636 at ClinicalTrials.govnct03521830 at ClinicalTrials.govDocuments that mention this clinical trial
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of nonmelanoma skin cancer
https://doi.org/10.1136/jitc-2021-004434
Immune microenvironment of basal cell carcinoma and tumor regression following combined PD-1/LAG-3 blockade
https://doi.org/10.1136/jitc-2023-007463
Rare basal cell metastasis of a basal-squamous skin collision tumour to the lung and axillary lymph node
https://doi.org/10.1136/bcr-2019-231487
428 Interim analysis of Phase 2 results for cemiplimab in patients with metastatic basal cell carcinoma (mBCC) who progressed on or are intolerant to hedgehog inhibitors (HHIs)
https://doi.org/10.1136/jitc-2020-sitc2020.0428
Documents that mention this clinical trial
Update in the treatment of non-melanoma skin cancers: the use of PD-1 inhibitors in basal cell carcinoma and cutaneous squamous-cell carcinoma
https://doi.org/10.1136/jitc-2022-005082
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of nonmelanoma skin cancer
https://doi.org/10.1136/jitc-2021-004434
Immune microenvironment of basal cell carcinoma and tumor regression following combined PD-1/LAG-3 blockade
https://doi.org/10.1136/jitc-2023-007463
-
Funding
Funding for this research was provided by:
The Marilyn and Michael Glosserman Fund for Basal Cell Carcinoma and Melanoma Research (N/A)
National Institutes of Health (T32CA193145)
Bloomberg~Kimmel Institute for Cancer Immunotherapy, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University (N/A)
The Mark Foundation for Advanced Genomics and Imaging (N/A)
National Cancer Institute (R01 CA142779)
Bristol-Myers Squibb (N/A)
- License Information
